Pulmonary Prognostics
Use only in stable COPD patients
kg/m²
%
meters
Enter Data to Begin
Provide the multidimensional clinical parameters to assess long-term COPD prognosis.
Guidelines & Evidence
Verified
Last Review: 2026-07-09
When to Use
Primary Indications
Patients with confirmed COPD (post-bronchodilator FEV1/FVC < 0.70) for mortality risk stratification
Pretreatment assessment to guide need for supplemental oxygen, pulmonary rehabilitation, or lung volume reduction
Serial monitoring (every 6-12 months) to track disease progression and response to therapy
Listing for lung transplantation evaluation (BODE ≥ 7 indicates high priority)
Predicting hospitalization risk and healthcare utilization in COPD patients
Research inclusion criteria for clinical trials of novel COPD therapies
Clinical Utility
The BODE Index outperforms traditional GOLD staging (which relies solely on FEV1) by incorporating systemic manifestations of COPD: nutritional status (BMI), dyspnea perception, and functional exercise capacity. A 1-point increase in BODE score correlates with a 34% increase in all-cause mortality. It predicts respiratory-related hospitalizations (AUROC 0.76, 95% CI 0.72-0.80), need for long-term oxygen therapy, and response to pulmonary rehabilitation. The index also guides decisions for interventions: BODE ≥ 5 predicts benefit from lung volume reduction surgery in upper-lobe emphysema, while BODE ≥ 7 suggests 2-year mortality exceeds 40%, qualifying patients for earlier transplant listing.
Comparison with Alternative COPD Scores
| Tool | Components | Primary Outcome | Validation Populations | Strengths |
|---|---|---|---|---|
| BODE Index | BMI, FEV1%, mMRC, 6MWD | All-cause mortality | >15,000 patients across 10+ cohorts | Multidimensional, captures systemic effects |
| GOLD Staging | FEV1% only | Mortality (weak correlation) | All COPD patients | Simple, universally available |
| ADO Index | Age, Dyspnea (mMRC), FEV1% | 3-year mortality | Elderly COPD, primary care | Age-weighted, good for older adults |
| CODEX Index | Comorbidity, Obstruction (FEV1), Dyspnea, Exercise (6MWD) | Hospitalization, mortality | Severe COPD, exacerbators | Includes comorbidities (Charlson) |
| CAT Score | 8 symptom items (cough, sputum, chest tightness, energy, activity, sleep, confidence) | Health status, symptom burden | All COPD stages | Patient-reported, responsive to change |
| DOSE Index | Dyspnea (mMRC), Obstruction (FEV1), Smoking, Exacerbation frequency | Exacerbations, mortality | Primary care, moderate COPD | Simple, no exercise test needed |
Exclusion Criteria and Limitations
Patients unable to perform 6MWT (severe arthritis, neurologic impairment, unstable angina, recent MI within 1 month)
Acute COPD exacerbation within past 4 weeks (score should be calculated during stable state)
Non-COPD causes of airflow obstruction (asthma, bronchiectasis, cystic fibrosis, bronchiolitis obliterans)
Patients with BMI <12 kg/m² (extreme malnutrition, BODE score underestimates mortality)
Patients on chronic oxygen therapy at rest (6MWD significantly reduced, may overestimate BODE severity)
Left ventricular dysfunction (HFrEF <40%) - 6MWD limited by cardiac, not pulmonary disease
Pulmonary hypertension (mean PAP >35 mmHg) - exercise capacity limited by right heart failure
Age >85 years (limited validation, ADO index preferred for this population)
Comparison with GOLD Staging: Why BODE is Superior
GOLD Stage 2 (FEV1 50-80%) includes patients at dramatically different mortality risk: a 50-year-old with BMI 30, no dyspnea, and 400m 6MWD has 5-year mortality <10%, while a 75-year-old with BMI 19, mMRC 3, and 200m 6MWD has 5-year mortality >40% - both are GOLD Stage 2. The BODE Index resolves this heterogeneity by adding nutritional, symptom, and functional domains, providing 4 distinct mortality strata within each GOLD stage.
Injury/Pathophysiology Correlations
Each BODE component captures distinct aspects of COPD pathophysiology: FEV1% quantifies central airflow limitation due to small airways disease and emphysematous destruction. BMI reflects systemic inflammation (TNF-alpha, IL-6) and muscle wasting (sarcopenia) driven by chronic hypoxemia and inactivity. mMRC dyspnea score integrates ventilatory limitation (dynamic hyperinflation) with peripheral muscle dysfunction and respiratory drive. 6MWD measures integrated cardiopulmonary performance: oxygen delivery (cardiac output, hemoglobin), ventilatory efficiency (dead space, V/Q mismatch), and peripheral muscle metabolism (lactate threshold, mitochondrial function). The synergy among these components arises because each exacerbates the others: low FEV1 increases dyspnea and reduces activity, leading to deconditioning (lower 6MWD), muscle wasting (lower BMI), and further dyspnea - a downward spiral.
Last Comprehensive Review: 2026